← The library
Bremelanotide
Vyleesi / PT-141Sexual HealthEvidence grade
AFDA-approved Rx (labeled use)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions
Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.
PurposeSexual health
MechanismMelanocortin receptor agonist; indicated for premenopausal HSDD
EffectsMelanocortin receptor agonist; indicated for premenopausal HSDD
Dosing1.75 mg SC as needed ≥45 min before; max 1 dose/24h; max 8 doses/month
Bottom lineStrongest data when used for its labeled indication under clinician guidance.
Protocols · as published2 sourced
FDA labelVyleesi (premenopausal women with acquired, generalized HSDD)
RouteSubcutaneous (abdomen or thigh)
FrequencyAs needed, at least 45 minutes before anticipated sexual activity
Starting1.75 mg SC as needed
EscalationNone; fixed dose
Target1.75 mg SC as needed
MaximumNo more than one dose within 24 hours; more than 8 doses per month not recommended
Discontinue after 8 weeks if no improvement. Use in men is off-label.
SourceVyleesi label (FDA) ↗
Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous
FrequencyOn demand
Starting1.75 mg (mirrors the label)
EscalationNone ("fixed on-demand protocol")
Target1.75 mg on demand
CycleOn-demand; label limits of 1 per 24 h and 8 per month
Batches on filenone
No tested batches on file.
Cautions & interactions
Can raise BP, nausea/flushing; not for performance enhancement; avoid in uncontrolled HTN/CVD
Can raise BP/HR; avoid with uncontrolled HTN/CVD; caution with antihypertensives; nausea common.
CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.